D. Mayeur

发表

Physicians’ decision about long-term thromboprophylaxis in cancer outpatients: CAT AXIS, a case vignette study on clinical practice in France

F. Scotté, G. Meyer, I. Elalamy, 2018, Supportive Care in Cancer.

A risk model for severe anemia to select cancer patients for primary prophylaxis with epoetin alpha: a prospective randomized controlled trial of the ELYPSE study group.

J. Blay, A. Le Cesne, P. Biron, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

French recommendations for osteoporosis prevention and treatment in patients with prostate cancer treated by androgen deprivation.

E. Lespessailles, J. Bonneterre, K. Briot, 2019, Joint, bone, spine : revue du rhumatisme.

Provision of palliative care and pain management services for oncology patients.

P. Marchetti, A. Kopf, R. Voltz, 2013, Journal of the National Comprehensive Cancer Network : JNCCN.

The official French guidelines to protect patients with cancer against SARS-CoV-2 infection

A. Ravaud, P. Giraud, R. Guimbaud, 2020, The Lancet Oncology.

Management of rare ovarian cancers: the experience of the French website "Observatory for rare malignant tumours of the ovaries" by the GINECO group: interim analysis of the first 100 patients.

C. Tournigand, B. Weber, I. Treilleux, 2010, Gynecologic oncology.

French Recommendations on Strategies for Preventing and Treating Osteoporosis Induced by Adjuvant Breast Cancer Therapies.

E. Lespessailles, J. Bonneterre, K. Briot, 2019, Joint, bone, spine : revue du rhumatisme.

Symptomatic treatment with lanreotide microparticles in inoperable bowel obstruction resulting from peritoneal carcinomatosis: a randomized, double-blind, placebo-controlled phase III study.

P. Mariani, O. Béatrix, P. Maisonobe, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[SARS-CoV-2/COVID 19 Infection and Solid Cancers: Synthesis of Recommendations for Health Professionals].

A. Ravaud, R. Guimbaud, J. Lotz, 2020, Bulletin du cancer.

Prevention and treatment of cancer-associated thrombosis in France: A national survey among vascular disease and supportive care specialists.

A. Lamblin, F. Scotté, G. Pernod, 2017, Journal de medecine vasculaire.

Management of Cancer-Associated Thrombosis in France: A National Survey among Vascular Disease and Supportive Care Specialists

G. Mahé, L. Bertoletti, C. Chapelle, 2022, Cancers.

Subcutaneous recombinant interleukin-2 (rIL-2) in out-patients with metastatic renal cell carcinoma. Results of a multicenter SCAPP1 trial.

E. Pujade-Lauraine, J. Andrieu, P. Grise, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

Molecular intrinsic subtypes, genomic, and immune landscapes of BRCA-proficient but HRD-high ER-positive/HER2-negative early breast cancers

R. Boidot, F. Ghiringhelli, S. Ladoire, 2022, Breast Cancer Research.

Management of venous thromboembolism in cancer patients: the economic burden of hospitalizations

I. Mahé, I. Krakowski, D. Mayeur, 2016, Supportive Care in Cancer.

Seroprevalence of SARS-CoV-2 among the staff and patients of a French cancer centre after first lockdown: The canSEROcov study

C. Coutant, A. Bertaut, Jean-David Fumet, 2021, European Journal of Cancer.

Efficacy of platinum-based chemotherapy in metastatic breast cancer and HRD biomarkers: utility of exome sequencing

R. Boidot, F. Ghiringhelli, S. Ladoire, 2022, npj Breast Cancer.

Clinical Utility of Genomic Tests Evaluating Homologous Recombination Repair Deficiency (HRD) for Treatment Decisions in Early and Metastatic Breast Cancer

R. Boidot, F. Ghiringhelli, S. Ladoire, 2023, Cancers.

Symptomatic Treatment With Lanreotide Microparticles in Inoperable Bowel Obstruction Resulting From Peritoneal Carcinomatosis: A Randomized, Double-blind, Placebo-controlled Phase III Study

P. Mariani, O. Béatrix, P. Maisonobe, 2013 .

A case of chronic neutrophilic leukemia with deletion (11)(q23).

R. Berger, C. Terré, D. Mayeur, 1999, Cancer genetics and cytogenetics.

Parallel evolution and differences in seroprevalence of SARS-CoV-2 antibody between patients with cancer and health care workers in a tertiary cancer centre during the first and second wave of COVID-19 pandemic: canSEROcov-II cross-sectional study

C. Coutant, A. Bertaut, Jean-David Fumet, 2022, European Journal of Cancer.

A Pragmatic Study Evaluating NEPA Versus Aprepitant for Prevention of Chemotherapy‐Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy

L. Zelek, B. Chauffert, F. Scotté, 2021, The oncologist.

Subcutaneous interleukin-2 and interferon alfa administration in patients with metastatic renal cell carcinoma: final results of SCAPP III, a large, multicenter, phase II, nonrandomized study with sequential analysis design--the Subcutaneous Administration Propeukin Program Cooperative Group.

C. Tournigand, S. Oudard, P. Cottu, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pharmacokinetic/Pharmacodynamic Model of Neutropenia in Real-Life Palbociclib-Treated Patients

Jean-David Fumet, S. Ladoire, B. Royer, 2021, Pharmaceutics.

Population Pharmacokinetics of Palbociclib in a Real-World Situation

Jean-David Fumet, S. Ladoire, B. Royer, 2021, Pharmaceuticals.

Outpatient treatment with subcutaneous interleukin-2 and interferon alfa administration in combination with fluorouracil in patients with metastatic renal cell carcinoma: results of a sequential nonrandomized phase II study. Subcutaneous Administration Propeukin Program Cooperative Group.

C. Chastang, A. Monnier, Y. Chrétien, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High-dose sequential epirubicin and cyclophosphamide with peripheral blood stem cell support for advanced breast cancer: results of a phase II study

M. Espié, A. Roquancourt, A. de Roquancourt, 2001, British Journal of Cancer.

Extended Anticoagulant Treatment with Full- or Reduced-Dose Apixaban in Patients with Cancer-Associated Venous Thromboembolism: Rationale and Design of the API-CAT Study

E. Vicaut, A. Torbicki, C. Samama, 2021, Thrombosis and Haemostasis.

6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

C. Tournigand, M. Espié, B. Weber, 2019, The Lancet.

Phase II study of gemcitabine in combination with docetaxel in patients with advanced pancreatic carcinoma. Preliminary results

C. Bouleuc, E. Pujade-Lauraine, T. Aparicio, 2005 .

Towards optimal use of antithrombotic therapy of people with cancer at the end of life: A research protocol for the development and implementation of the SERENITY shared decision support tool.

F. Skjøth, A. Ording, N. Chavannes, 2023, Thrombosis research.

Trastuzumab-emtansine induced pleural and pericardial effusions

Antonin Schmitt, D. Mayeur, A. Grandvuillemin, 2021, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Taxane rechallenge during metastatic disease in HER-2 negative breast cancer patients: Clinical activity, tolerance and survival results

A. Bertaut, S. Ladoire, C. Kaderbhai, 2023, Breast.

189O A phase II study of patritumab deruxtecan (HER3-DXd), in patients (pts) with advanced breast cancer (ABC), with biomarker analysis to characterize response to therapy (ICARUS-BREAST01)

S. Michiels, M. Lacroix-Triki, B. Pistilli, 2023, ESMO Open.

PROPERTY: study protocol for a randomized, double-blind, multicenter placebo-controlled trial assessing neurotoxicity in patients with metastatic gastrointestinal cancer taking PHYCOCARE® during oxaliplatin-based chemotherapy

C. Volteau, Y. Péréon, C. Pétorin, 2023, Trials.

Pathologic complete response and survival in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy

C. Coutant, A. Bertaut, S. Ladoire, 2023, Breast Cancer.